A

Assembly Biosciences
D

ASMB

19.010
USD
0.56
(3.04%)
مغلق
حجم التداول
611
الربح لكل سهم
-5
العائد الربحي
-
P/E
-3
حجم السوق
145,189,883
أصول ذات صلة
ALNY
ALNY
1.29
(0.39%)
329.01 USD
A
ARWR
-0.520
(-3.20%)
15.740 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
E
ESPR
0.00500
(0.34%)
1.49500 USD
I
IONS
0.100
(0.24%)
42.240 USD
N
NTLA
0.830
(6.50%)
13.595 USD
R
RGNX
-0.17000
(-1.86%)
8.96000 USD
V
VYGR
-0.08000
(-2.41%)
3.23500 USD
المزيد
الأخبار المقالات

العنوان: Assembly Biosciences

القطاع: Healthcare
الصناعة: Biotechnology
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.